My takeaway from the article was that the addressable market for srx has (even if trial results are not as positive as anticipated) increased due to:
1. Increase in the addressable market due to the salvage market expanding more than initially anticipated.
2. Treatment options being tailored for individuals specifically.
I dont think this was part of their thesis when they first invested in srx. Also I believe David Buckland brought over a great deal of knowledge about srx from his time at hunter hall, but he is CEO so this has obviously been passed down to the analysts.
My takeaway from the article was that the addressable market for...
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SRX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $74.27M | |||
| Open | High | Low | Value | Volume |
| 18.0¢ | 18.0¢ | 17.5¢ | $292.8K | 1.630M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 7394560 | 17.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 1260654 | 10 |
View Market Depth
| Last trade - 16.10pm 25/07/2024 (20 minute delay) ? |
| SRX (ASX) Chart |